Statement: Throughout the primary trial, one patient in cohort 1 developed issues with their vision.
Primary_evidence: Adverse Events 1:   Total: 34/214 (15.89%)   Leukocytosis 0/214 (0.00%)   Atrial fibrillation 0/214 (0.00%)   Cardiac failure congestive 0/214 (0.00%)   Pericardial effusion 1/214 (0.47%)   Cataract 0/214 (0.00%)   Macular fibrosis 0/214 (0.00%)   Constipation 2/214 (0.93%)   Diarrhoea 2/214 (0.93%)   Enterocolitis 0/214 (0.00%)   Ileus 1/214 (0.47%)   Nausea 3/214 (1.40%) Adverse Events 2:   Total: 27/213 (12.68%)   Leukocytosis 1/213 (0.47%)   Atrial fibrillation 1/213 (0.47%)   Cardiac failure congestive 1/213 (0.47%)   Pericardial effusion 0/213 (0.00%)   Cataract 1/213 (0.47%)   Macular fibrosis 1/213 (0.47%)   Constipation 1/213 (0.47%)   Diarrhoea 1/213 (0.47%)   Enterocolitis 1/213 (0.47%)   Ileus 0/213 (0.00%)   Nausea 0/213 (0.00%)